- News Releases
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a majority of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in about 25 percent of patients — and oncologists haven’t been able to identify these women before treatment. This situation may soon change, according to a Mayo Clinic study being presented this week at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
EMBARGOED news release: Dr. Perez
Sound bites with Edith Perez, M.D., are available in the downloads below
Expert title for broadcast cg: Dr. Edith Perez, Mayo Clinic Oncologist
Shortly before Thanksgiving 2021, Jerry Haines, a part-time farmer and retired butter and cheesemaker, was helping another farmer with fall chores. He felt good but ...
May is Bladder Cancer Awareness Month, which makes this a good time to learn about the risk factors for bladder cancer and what you can do ...
May is Brain Cancer Awareness Month, which makes this a good time to learn about metastatic brain cancer. Overall, the chance that a person will develop ...